Effect of CGS 16949A on Aromatization in Breast Cancer Patients
Author Information
Author(s): P.E. L0nning, S. Jacobs, A. Jones, B. Haynes, T. Powles, M. Dowsett
Primary Institution: The Royal Marsden Hospital
Hypothesis
CGS 16949A inhibits the aromatization of androstenedione into oestrone in postmenopausal women with breast cancer.
Conclusion
CGS 16949A at a dose of 2 mg b.d. results in over 90% inhibition of aromatization, while 1 mg b.d. causes submaximal inhibition.
Supporting Evidence
- CGS 16949A inhibited aromatisation by a mean value of 82.4% at a dose of 1 mg b.d.
- At a dose of 2 mg b.d., aromatisation was inhibited by a mean of 92.6%.
- Previous treatments included tamoxifen and aminoglutethimide.
Takeaway
This study tested a new drug on women with breast cancer to see how well it stops the body from making a certain hormone. The higher dose worked better than the lower dose.
Methodology
The study involved injecting a mixture of radioactive androstenedione and oestrone into patients and measuring the isotope ratios in urine collected over 96 hours.
Limitations
The study had a small sample size and did not assess plasma drug levels.
Participant Demographics
Eight postmenopausal breast cancer patients with a mean age of 64.9 years.
Want to read the original?
Access the complete publication on the publisher's website